ATH-1017 not checked

LeonaBio

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe”In the company’s words, NCT04488419 on ClinicalTrials.gov
Tested for
Alzheimer Disease (3 trials), Dementia of Alzheimer Type (2 trials), Parkinson Disease Dementia, Dementia With Lewy Bodies
Main trialPhase 2/3
“This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.”In the company’s words, NCT04488419 on ClinicalTrials.gov

Other drugs for Alzheimer Disease

All 91 drugs for Alzheimer Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Completed 15 Jul 2024 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Phase 2/3Terminated 23 Oct 2024 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Phase 2Completed 20 May 2022 A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
Phase 2Terminated 19 Apr 2023 ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ATH-1017

Following is part of Solo: you see every change to ATH-1017 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in